Dendreon Ends Year With $109M
Luke Timmerman3/12/09
Dendreon, the Seattle biotech company developing an immune-boosting treatment for cancer, said today it finished ended 2008 with $108.5 million in cash and investments. The company (NASDAQ: DNDN) didn’t provide a financial forecast for how much of that it plans to spend in 2009. Dendreon is awaiting final results next month from a trial of 500 men that will determine whether its drug, sipuleucel-T (Provenge) is able to help men with terminal prostate cancer to live longer.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
